Valuation: Jazz Pharmaceuticals plc

Market Cap 13.42B 12.04B 11.13B 10.08B 18.84B 1,278B 19.07B 133B 53.03B 669B 50.37B 49.31B 2,124B P/E 2026 *
21.3x
P/E 2027 * 12.7x
Enterprise Value 15.73B 14.11B 13.05B 11.82B 22.08B 1,498B 22.34B 156B 62.13B 784B 59.02B 57.78B 2,489B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 2.75x
Free-Float
96.83%
Yield 2026 *
-
Yield 2027 * -
1 day-1.49%
1 week-3.57%
Current month-11.71%
1 month-14.22%
3 months-20.44%
6 months+0.21%
Current year+20.24%
1 week 202.3
Extreme 202.3
216.43
1 month 202.3
Extreme 202.3
238.87
Current year 156.95
Extreme 156.95
266.38
1 year 128.8
Extreme 128.8
266.38
3 years 95.49
Extreme 95.49
266.38
5 years 95.49
Extreme 95.49
266.38
10 years 86.88
Extreme 86.88
266.38
Manager TitleAgeSince
Chief Executive Officer 54 10/08/2025
Director of Finance/CFO 62 29/02/2024
Chief Tech/Sci/R&D Officer 54 31/07/2023
Director TitleAgeSince
Chairman 62 28/02/2003
Director/Board Member 65 17/01/2012
Director/Board Member 66 31/12/2009
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Sell

Chief Executive Officer

-2,000 0.0031%
01/10/26 Sell

Founder

-6,000 0.0092%
10/09/26 Sell

General Counsel

-1,200 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-3.57%+47.98%+63.58% 13.42B
+0.37%+1.42%+57.15%+127.82% 1,143B
+0.95%+5.37%+45.31%+84.74% 647B
+0.29%+1.08%+26.52%+102.89% 506B
-0.05%+1.73%+52.74%+65.27% 384B
-1.10%-6.26%+61.44%+36.83% 350B
+0.34%+1.84%+30.70%+52.69% 293B
-0.45%+1.19%+2.89%+24.92% 265B
+0.42%+2.84%+54.33%+71.28% 242B
-0.08%+3.89%+35.35%+105.16% 197B
Average -0.07%+0.43%+41.44%+73.52% 404.1B
Weighted average by Cap. +0.19%+0.69%+44.63%+87.07%

Financials

2026 *2027 *
Net sales 4.72B 4.24B 3.92B 3.55B 6.63B 450B 6.71B 46.84B 18.66B 235B 17.72B 17.35B 747B 4.99B 4.48B 4.14B 3.75B 7.01B 476B 7.09B 49.53B 19.73B 249B 18.74B 18.34B 790B
Net income 635M 569M 526M 477M 891M 60.44B 902M 6.29B 2.51B 31.63B 2.38B 2.33B 100B 1.13B 1.01B 938M 850M 1.59B 108B 1.61B 11.22B 4.47B 56.37B 4.24B 4.16B 179B
Net Debt 2.31B 2.07B 1.91B 1.73B 3.24B 220B 3.28B 22.87B 9.11B 115B 8.65B 8.47B 365B 326M 292M 270M 245M 457M 31.01B 462M 3.23B 1.29B 16.22B 1.22B 1.2B 51.51B
Projected Income Statement - Annual - Jazz Pharmaceuticals plc
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
28/10/26 US$204.41 -1.15% 526,887
27/10/26 US$206.78 +0.53% 605,813
26/10/26 US$205.70 -3.88% 970,043
23/10/26 US$214.00 -0.30% 560,601
22/10/26 US$214.65 +1.26% 783,806
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Jazz Pharmaceuticals plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
206.78USD
Average target price
294.27USD
Spread / Average Target
+42.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jazz Pharmaceuticals plc
  1. Stock Market
  2. Stocks
  3. JAZZ Stock